Bicycle therapeutics appoints jose-carlos gutierrez-ramos, ph.d., to its board of directors

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the appointment of jose-carlos (“jc”) gutierrez-ramos, ph.d., to its board of directors. dr. gutierrez-ramos previously served as the chair of bicycle's scientific advisory board and has extensive experience in leading biopharmaceutical companies a
BCYC Ratings Summary
BCYC Quant Ranking